Stifel Financial
ASND icon

Stifel Financial’s Ascendis Pharma A/S ASND Stock Holding History

Stifel Financial’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.77M Buy
21,640
+2,043
+10% +$477K ﹤0.01% 1331
2026
Q1 		$4.48M Sell
19,597
-601
-3% -$135K ﹤0.01% 1410
2025
Q4 		$4.31M Sell
20,198
-176
-0.9% -$36.3K ﹤0.01% 1419
2025
Q3 		$4.05M Buy
20,374
+404
+2% +$75.4K ﹤0.01% 1417
2025
Q2 		$3.45M Buy
19,970
+3,874
+24% +$631K ﹤0.01% 1466
2025
Q1 		$2.51M Sell
16,096
-1,001
-6% -$143K ﹤0.01% 1605
2024
Q4 		$2.35M Buy
17,097
+4,534
+36% +$596K ﹤0.01% 1653
2024
Q3 		$1.88M Sell
12,563
-544
-4% -$73.5K ﹤0.01% 1819
2024
Q2 		$1.79M Sell
13,107
-53
-0.4% -$7.21K ﹤0.01% 1794
2024
Q1 		$1.99M Buy
13,160
+579
+5% +$82.6K ﹤0.01% 1721
2023
Q4 		$1.58M Sell
12,581
-12
-0.1% -$1.2K ﹤0.01% 1828
2023
Q3 		$1.18M Buy
12,593
+2,941
+30% +$275K ﹤0.01% 1935
2023
Q2 		$861K Buy
9,652
+484
+5% +$42.1K ﹤0.01% 2174
2023
Q1 		$983K Sell
9,168
-205
-2% -$23.5K ﹤0.01% 2074
2022
Q4 		$1.14M Buy
9,373
+586
+7% +$68K ﹤0.01% 1896
2022
Q3 		$907K Buy
8,787
+497
+6% +$47.1K ﹤0.01% 2039
2022
Q2 		$771K Buy
8,290
+12
+0.1% +$1.13K ﹤0.01% 2185
2022
Q1 		$972K Sell
8,278
-165
-2% -$19.1K ﹤0.01% 2133
2021
Q4 		$1.14M Buy
8,443
+954
+13% +$142K ﹤0.01% 2035
2021
Q3 		$1.19M Buy
7,489
+962
+15% +$132K ﹤0.01% 1949
2021
Q2 		$859K Sell
6,527
-89
-1% -$11.9K ﹤0.01% 2214
2021
Q1 		$853K Sell
6,616
-42
-0.6% -$6.38K ﹤0.01% 2097
2020
Q4 		$1.11M Sell
6,658
-56
-0.8% -$9.26K ﹤0.01% 1768
2020
Q3 		$1.04M Buy
6,714
+268
+4% +$38.5K ﹤0.01% 1603
2020
Q2 		$953K Sell
6,446
-335
-5% -$46K ﹤0.01% 1589
2020
Q1 		$762K Buy
6,781
+69
+1% +$8.96K ﹤0.01% 1601
2019
Q4 		$933K Buy
6,712
+2,509
+60% +$279K ﹤0.01% 1882
2019
Q3 		$407K Buy
4,203
+1,616
+62% +$180K ﹤0.01% 2275
2019
Q2 		$295K Sell
2,587
-147
-5% -$17.6K ﹤0.01% 2510
2019
Q1 		$323K Buy
+2,734
New +$239K ﹤0.01% 2314

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Stifel Financial's ASND Position: Q2 2026 in Review

Stifel Financial increased its Ascendis Pharma A/S (ASND) stake by 10% in Q2 2026, buying an estimated $477K and bringing the position to 21,640 shares worth $5.77M. The position accounts for ﹤0.01% of the portfolio, ranked #1331.

Stifel Financial first reported a position in ASND in Q1 2019 and has held it in 30 quarters since. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • Stifel Financial held 21,640 shares of Ascendis Pharma A/S worth $5.77M as of Q2 2026.
  • Stifel Financial bought 2,043 Ascendis Pharma A/S shares in Q2 2026, an estimated $477K.
  • Ascendis Pharma A/S made up ﹤0.01% of Stifel Financial's portfolio in Q2 2026, its #1331 holding.
  • Stifel Financial first reported a position in Ascendis Pharma A/S in Q1 2019 and has held it in 30 quarters since.
  • 312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Stifel Financial's 13F filing for Q2 2026, filed 12 Aug 2026.